Effects of the polo-like-kinase-1-inhibitor BI2536 in squamous cell carcinoma cell lines of the head and neck

Oncology Letters

Volumn 4, Issue 1, 2012, Pages 175-177

  Wagenblast, Jens ^a   Hirth, Daniel ^a   Thron, Laura ^a   Arnoldner, Christoph ^b   Diensthuber, Marc ^a   Stöver, Timo ^a   Hambek, Markus ^a  

^a GOETHE UNIVERSITY   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Apoptosis; BI2536; Growth inhibition; Squamous cell head and neck carcinoma cell lines

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG EFFICACY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; QUANTITATIVE ANALYSIS; SINGLE DRUG DOSE; TREATMENT OUTCOME;

EID: 84861312799     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.700     Document Type: Article

References (16)

1. Mehanna H, Paleri V, West CM and Nutting C: Head and neck cancer - Part 1: epidemiology, presentation, and prevention. BMJ 341: c4684, 2010.
2. Maden C, Beckmann AM, Thomas DB, McKnight B, Sherman KJ, Ashley RL, et al: Human papillomaviruses, herpes simplex viruses, and the risk of oral cancer in men. Am J Epidemiol 135: 1093-1102, 1992.
3. Wagenblast J, Hambek M, Baghi M, Gstottner W, Strebhardt K, Ackermann H, et al: Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines. J Cancer Res Clin Oncol 134: 323-330, 2008.
4. Renner AG, Dos Santos C, Recher C, Bailly C, Creancier L, Kruczynski A, et al: Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Blood 114: 659-662, 2009.
5. Van de Weerdt BC and Medema RH: Polo-like kinases: a team in control of the division. Cell Cycle 5: 853-864, 2006.
6. Steegmaier M, Hoffmann M, Baum A, Lenart P, Petronczki M, Krssak M, et al: BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 17: 316-322, 2007.
7. Takai N, Hamanaka R, Yoshimatsu J and Miyakawa I: Polo-like kinases (Plks) and cancer. Oncogene 24: 287-291, 2005.
8. Strebhardt K and Ullrich A: Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 6: 321-330, 2006.
9. Datta D, Banerjee P, Gasser M, Waaga-Gasser AM and Pal S: CXCR3-B can mediate growth-inhibitory signals in human renal cancer cells by down-regulating the expression of heme oxygenase-1. J Biol Chem 285: 36842-36848, 2010.
10. Ray RB, Raychoudhuri A, Steele R and Nerurkar P: Bitter melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis. Cancer Res 70: 1925-1931, 2010.
11. Holtrich U, Wolf G, Brauninger A, Karn T, Bohme B, Rubsamen-Waigmann H, et al: Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. Proc Natl Acad Sci USA 91: 1736-1740, 1994.
12. Wolf G, Elez R, Doermer A, Holtrich U, Ackermann H, Stutte HJ, et al: Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 14: 543-549, 1997.
13. Knecht R, Elez R, Oechler M, Solbach C, von Ilberg C and Strebhardt K: Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res 59: 2794-2797, 1999.
14. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al: Cancer statistics. CA Cancer J Clin 55: 10-30, 2005.
15. Wagenblast J, Baghi M, Arnoldner C, Bisdas S, Gstottner W, Ackermann H, et al: Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines. J Cancer Res Clin Oncol 135: 387-393, 2009.
16. Schoffski P, Blay JY, De Greve J, Brain E, Machiels JP, Soria JC, et al: Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). Eur J Cancer 46: 2206-2215, 2010.